Biocept Stock News

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted an inducement stock option to purchase 134,550 shares of its common stock to Darrell Taylor, its new Senior Vice President, General Counsel and Chief Compliance Officer. The inducement stock option has a grant date of February 28, 2022, and was granted as an inducement material to Mr. Taylor’s entering into employment with Biocep

Biocept Inc (NASDAQ:BIOC) (Biocept Inc (NASDAQ:BIOC)) has highlighted how its CNSide cerebrospinal fluid (CSF) assay could improve the treatment options for brain cancer patients. The biotech has been

PALM BEACH, FL , Feb. 18, 2022 /PRNewswire/ -- PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few years. Countries are racing to slow down the spread of the disease by implementing necessary measures and increasing sample testing. The growing demand for COVID-19 diagnostic procedures and products alone has created immense opportunities in the healthcare industry, thus augmenting the market value. According to Fortune Business Insights: "The PCR technique segment dominated the market in 2020. The dominance is attributable to the increased quantification of patent samples by the use of PCR. PCR adoption has also contributed to the considerable growth of the segment. Moreover, the launch of new PCR-based detection techniques is like to surge the demand of for PCR instruments in the upcoming years." For example, the emergence of the COVID-19 pandemic has led to an explosion of research on various combinations of compounds in laboratories to develop COVID-19 diagnostics and therapies.

Biocept (BIOC) appointed Samuel Riccitelli as interim president and CEO, succeeding Michael Nall.Riccitelli, who will remain chair of the board, recently served as CEO of Pathnostics,…

Biocept Inc (NASDAQ:BIOC) announced the appointments of Samuel Riccitelli as the company's new interim CEO as well as Antonino Morales as its interim chief financial officer (CFO). Biocept also said i

Biocept Inc (NASDAQ:BIOC) announced that it has appointed Darrell Taylor as the company's new senior vice president, general counsel and chief compliance officer.  Biocept said Taylor will lead essen

Biocept (BIOC) said the COVID-19 RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant.The company has received more than 40K samples for COVID-19…

Biocept Inc (NASDAQ:BIOC) announced that coronavirus (COVID-19) RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant.  The San Diego-based company said that it contin

Here is how Biocept, Inc. (BIOC) and BioVie Inc. (BIVI) have performed compared to their sector so far this year.

Here is how Biocept, Inc. (BIOC) and BioVie Inc. (BIVI) have performed compared to their sector so far this year.

Zacks Investment Research upgraded shares of Biocept (NASDAQ:BIOC) from a hold rating to a buy rating in a research note issued to investors on Monday morning, Zacks.com reports. The brokerage currently has $4.25 price objective on the medical research companys stock. According to Zacks, Biocept, Inc. is a commercial stage oncology diagnostics company. It has []

Zacks Investment Research upgraded shares of Biocept (NASDAQ:BIOC) from a hold rating to a buy rating in a report released on Monday, Zacks.com reports. Zacks Investment Research currently has $4.25 price target on the medical research company’s stock. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms […] The post Biocept (NASDAQ:BIOC) Upgraded at Zacks Investment Research appeared first on ETF Daily News .

Zacks Investment Research downgraded shares of Biocept (NASDAQ:BIOC) from a buy rating to a hold rating in a report issued on Friday morning, Zacks.com reports. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing […]